Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Status: Enrolling
Updated:  6/6/2017
Ohio State University
1959
mi
from 91732
Columbus, OH
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Status: Enrolling
Updated: 6/6/2017
Ohio State University
1959
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Status: Enrolling
Updated:  6/6/2017
University of Pittsburgh
2121
mi
from 91732
Pittsburgh, PA
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Status: Enrolling
Updated: 6/6/2017
University of Pittsburgh
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone in Patients With Locally/Regionally Advanced/Recurrent Melanoma: A Randomized Efficacy, Safety and Biomarker Study
Status: Enrolling
Updated:  6/6/2017
UPMC Cancer Center - Hillman Cancer Center
2122
mi
from 91732
Pittsburgh, PA
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone in Patients With Locally/Regionally Advanced/Recurrent Melanoma: A Randomized Efficacy, Safety and Biomarker Study
Status: Enrolling
Updated: 6/6/2017
UPMC Cancer Center - Hillman Cancer Center
2122
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Safety and Immunogenicity of Vaccination With Multi-Epitope Peptide Vaccine Containing MART-1, gp100, and Tyrosinase Peptides Given With the Combination of GMCSF and CpG Oligonucleotide (CpG 7909) in ISA-Oil Adjuvant for Patients With Recurrent Inoperable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  6/21/2017
UPMC Cancer Centers
2122
mi
from 91732
Pittsburgh, PA
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Safety and Immunogenicity of Vaccination With Multi-Epitope Peptide Vaccine Containing MART-1, gp100, and Tyrosinase Peptides Given With the Combination of GMCSF and CpG Oligonucleotide (CpG 7909) in ISA-Oil Adjuvant for Patients With Recurrent Inoperable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 6/21/2017
UPMC Cancer Centers
2122
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Optical Imaging of Skin Cancers for Margin Delineation of Non-Melanoma Skin Cancers
Evaluation of Optical Imaging for Margin Delineation of Non-Melanoma Skin Cancers
Status: Enrolling
Updated:  6/27/2017
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Optical Imaging of Skin Cancers for Margin Delineation of Non-Melanoma Skin Cancers
Evaluation of Optical Imaging for Margin Delineation of Non-Melanoma Skin Cancers
Status: Enrolling
Updated: 6/27/2017
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Safety of Either a Single or Two IV Doses of Orbactiv in Subjects With ABSSSI
A Double-Blind, Randomized Study to Evaluate the Safety of Either a Single 1200-mg Intravenous (IV) Dose of Orbactiv™ (Oritavancin) and Placebo or Two IV Doses of Orbactiv™ in Subjects Being Treated for Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Status: Enrolling
Updated:  6/28/2017
South Jersey Infectious Disease
2409
mi
from 91732
Somers Point, NJ
Safety of Either a Single or Two IV Doses of Orbactiv in Subjects With ABSSSI
A Double-Blind, Randomized Study to Evaluate the Safety of Either a Single 1200-mg Intravenous (IV) Dose of Orbactiv™ (Oritavancin) and Placebo or Two IV Doses of Orbactiv™ in Subjects Being Treated for Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Status: Enrolling
Updated: 6/28/2017
South Jersey Infectious Disease
2409
mi
from 91732
Somers Point, NJ
Click here to add this to my saved trials
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
A Phase II Study of Cell Transfer Therapy for Metastatic Melanoma Using 41BB Selected Tumor Infiltrating Lymphocytes Plus IL-2 Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen
Status: Enrolling
Updated:  7/6/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
A Phase II Study of Cell Transfer Therapy for Metastatic Melanoma Using 41BB Selected Tumor Infiltrating Lymphocytes Plus IL-2 Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen
Status: Enrolling
Updated: 7/6/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Use of Shade in U.S. and Australian City Parks
Norms and Built Environment: Use of Shade in U.S. and Australian City Parks
Status: Enrolling
Updated:  7/24/2017
Klein Buendel, Inc
808
mi
from 91732
Golden, CO
Use of Shade in U.S. and Australian City Parks
Norms and Built Environment: Use of Shade in U.S. and Australian City Parks
Status: Enrolling
Updated: 7/24/2017
Klein Buendel, Inc
808
mi
from 91732
Golden, CO
Click here to add this to my saved trials
Use of Shade in U.S. and Australian City Parks
Norms and Built Environment: Use of Shade in U.S. and Australian City Parks
Status: Enrolling
Updated:  7/24/2017
Cancer Council Victoria
7949
mi
from 91732
Melbourne,
Use of Shade in U.S. and Australian City Parks
Norms and Built Environment: Use of Shade in U.S. and Australian City Parks
Status: Enrolling
Updated: 7/24/2017
Cancer Council Victoria
7949
mi
from 91732
Melbourne,
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
24
mi
from 91732
Los Angeles, CA
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
24
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
356
mi
from 91732
San Francisco, CA
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
356
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
26
mi
from 91732
Santa Monica, CA
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
26
mi
from 91732
Santa Monica, CA
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
2486
mi
from 91732
New Haven, CT
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
2486
mi
from 91732
New Haven, CT
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
2131
mi
from 91732
Jacksonville, FL
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
2131
mi
from 91732
Jacksonville, FL
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
2324
mi
from 91732
Miami Beach, FL
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
2324
mi
from 91732
Miami Beach, FL
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
1730
mi
from 91732
Chicago, IL
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
1793
mi
from 91732
Indianapolis, IN
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
1793
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
2301
mi
from 91732
Lutherville-Timonium, MD
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
2301
mi
from 91732
Lutherville-Timonium, MD
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
2435
mi
from 91732
New York, NY
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
1938
mi
from 91732
Toledo, OH
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
1938
mi
from 91732
Toledo, OH
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
2121
mi
from 91732
Pittsburgh, PA
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
mi
from 91732
Waratah,
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
mi
from 91732
Waratah,
Click here to add this to my saved trials
Strategies to Promote Skin Health
Strategies to Promote Skin Health
Status: Enrolling
Updated:  8/1/2017
San Diego State University
103
mi
from 91732
San Diego, CA
Strategies to Promote Skin Health
Strategies to Promote Skin Health
Status: Enrolling
Updated: 8/1/2017
San Diego State University
103
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
Pilot Study of IFN α2b for Melanoma Patients
Pilot Analysis of the Effects of IFN α2b Upon the Molecular Profile of Regional Lymph Nodes in Melanoma Patients With and Without Tumor-Involved Sentinel Lymph Nodes
Status: Enrolling
Updated:  8/3/2017
UPMC - Hillman Cancer Center
2122
mi
from 91732
Pittsburgh, PA
Pilot Study of IFN α2b for Melanoma Patients
Pilot Analysis of the Effects of IFN α2b Upon the Molecular Profile of Regional Lymph Nodes in Melanoma Patients With and Without Tumor-Involved Sentinel Lymph Nodes
Status: Enrolling
Updated: 8/3/2017
UPMC - Hillman Cancer Center
2122
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Epigenetically-Modified Autologous Tumor Cell Vaccs and ISCOMATRIX(TM) Adjuvant With Metronomic Oral Cyclophosphamide and Celecoxib in Pts Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura or Mediastinum
Status: Enrolling
Updated:  8/3/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Epigenetically-Modified Autologous Tumor Cell Vaccs and ISCOMATRIX(TM) Adjuvant With Metronomic Oral Cyclophosphamide and Celecoxib in Pts Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura or Mediastinum
Status: Enrolling
Updated: 8/3/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated:  8/29/2017
GSK Investigational Site
24
mi
from 91732
Los Angeles, CA
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated: 8/29/2017
GSK Investigational Site
24
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated:  8/29/2017
GSK Investigational Site
356
mi
from 91732
San Francisco, CA
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated: 8/29/2017
GSK Investigational Site
356
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated:  8/29/2017
GSK Investigational Site
2373
mi
from 91732
Philadelphia, PA
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated: 8/29/2017
GSK Investigational Site
2373
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated:  8/29/2017
GSK Investigational Site
1762
mi
from 91732
Nashville, TN
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated: 8/29/2017
GSK Investigational Site
1762
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated:  8/29/2017
GSK Investigational Site
1357
mi
from 91732
Houston, TX
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated: 8/29/2017
GSK Investigational Site
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated:  8/29/2017
GSK Investigational Site
7453
mi
from 91732
Newcastle,
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated: 8/29/2017
GSK Investigational Site
7453
mi
from 91732
Newcastle,
Click here to add this to my saved trials
Multiple Antigen-Engineered DC Vaccine for Melanoma
A Phase I Trial Testing Multiple Antigen-Engineered DC Followed by IFNa2b Boost for Immunization of HLA-Unrestricted Melanoma Patients
Status: Enrolling
Updated:  8/30/2017
University of Pittsburgh Cancer Institute
2122
mi
from 91732
Pittsburgh, PA
Multiple Antigen-Engineered DC Vaccine for Melanoma
A Phase I Trial Testing Multiple Antigen-Engineered DC Followed by IFNa2b Boost for Immunization of HLA-Unrestricted Melanoma Patients
Status: Enrolling
Updated: 8/30/2017
University of Pittsburgh Cancer Institute
2122
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Dermatology Research Associate
23
mi
from 91732
Los Angeles, CA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Dermatology Research Associate
23
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Stanford University
329
mi
from 91732
Palo Alto, CA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Stanford University
329
mi
from 91732
Palo Alto, CA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Skin Surgery Medical Group, Inc.
98
mi
from 91732
San Diego, CA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Skin Surgery Medical Group, Inc.
98
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
California Pacific Medical Center Research Institute
400
mi
from 91732
Santa Rosa, CA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
California Pacific Medical Center Research Institute
400
mi
from 91732
Santa Rosa, CA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Advanced Derm & Cosmetic Surg
2185
mi
from 91732
Ormond Beach, FL
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Advanced Derm & Cosmetic Surg
2185
mi
from 91732
Ormond Beach, FL
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Skin and Cancer Associates and the Center for Cosmetic Enhancement
2308
mi
from 91732
Plantation, FL
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Skin and Cancer Associates and the Center for Cosmetic Enhancement
2308
mi
from 91732
Plantation, FL
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Emory University Clinic
1922
mi
from 91732
Atlanta, GA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Emory University Clinic
1922
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Laser & Skin Surgery Center of Indiana
1795
mi
from 91732
Carmel, IN
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Laser & Skin Surgery Center of Indiana
1795
mi
from 91732
Carmel, IN
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Beverly Hospital;Oncology Center Pharmacy
2586
mi
from 91732
Beverly, MA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Beverly Hospital;Oncology Center Pharmacy
2586
mi
from 91732
Beverly, MA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Saint Louis University School of Medicine; Department of Dermatology
1570
mi
from 91732
Saint Louis, MO
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Saint Louis University School of Medicine; Department of Dermatology
1570
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Washington University School of Medicine
1569
mi
from 91732
Saint Louis, MO
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Washington University School of Medicine
1569
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Long Island Skin Cancer and Dermatologic Surgery
2472
mi
from 91732
Smithtown, NY
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Long Island Skin Cancer and Dermatologic Surgery
2472
mi
from 91732
Smithtown, NY
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Mariwalla Dermatology
2470
mi
from 91732
West Islip, NY
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Mariwalla Dermatology
2470
mi
from 91732
West Islip, NY
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
The Skin Surgery Center
2123
mi
from 91732
Winston-Salem, NC
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
The Skin Surgery Center
2123
mi
from 91732
Winston-Salem, NC
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Ohio State University
1959
mi
from 91732
Columbus, OH
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Ohio State University
1959
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Penn State Milton S. Hershey Medical Center
2296
mi
from 91732
Hershey, PA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Penn State Milton S. Hershey Medical Center
2296
mi
from 91732
Hershey, PA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Dermatology and Laser Center of Charleston
2184
mi
from 91732
Charleston, SC
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Dermatology and Laser Center of Charleston
2184
mi
from 91732
Charleston, SC
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
LKH Innsbruck; Universitätsklinik für Dermatologie
6001
mi
from 91732
Innsbruck,
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
LKH Innsbruck; Universitätsklinik für Dermatologie
6001
mi
from 91732
Innsbruck,
Click here to add this to my saved trials